Ductal Carcinoma in Situ of the Breast;Diagnostic Assessment and Treatment

Farrow JH Current concepts in the detection and treatment of the earliest of the early breast cancers. Cancer 1970;25:468–477.

Millis RR Thynne GS In situ intraduct carcinoma of the breast: A long term follow-up study. Br J Surg 1975;62:957–962.

Westbrook KC Gallager HS Intraductal carcinoma of the breast. A comparative study. Am J Surg 1975; 130: 667–670.

Ashikari R Huvos AG Snyder RE Prospective study of non infiltrating carcinoma of the breast. Cancer 1977;39:435–439.

Sunshine JA Moseley HS Fletcher WS Krippaehne WW Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. Am J Surg 1985; 150: 44–51.

Ciatto S Bonardi R Cataliotti L Cardona G Intraductal breast carcinoma. Review of a multicenter series of 350 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Tumori 1990; 76: 552–554.

Silverstein MJ Waisman JR Gamagami P .: Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990; 66: 102–108.

Alpers CE Wellings SR The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 1985;16:796–807.

Nielsen M Autopsy studies of the occurrence of cancerous, atypical and benign epithelial lesions in the female breast. APMIS Suppl 1989;10:1–56.

Bhathal PS Brown RW Lesueur GC Russell IS Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 1985;51(2):271–8.

Eusebi V Feudale E Foschini MP .: Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994;11:223–235.

Page DL Dupont WD Rogers LW Jensen RA Schuyler PA Continued local recurrence of carcinoma 15–25 years after diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995;76:1197–1200.

Rosen PP Braun DW Jr Kinne DE The clinical significance of pre-invasive breast carcinoma. Cancer 1980;46:919–925.

Lewis D Geschickter CF Comedocarcinoma of the breast. Arch Surg 1938;36:225–244.

Shapiro S Coleman EA Broeders M Codd M de Koning H Fracheboud J Moss S Paci E Stachenko S Ballard-Barbash R Breast cancer screening programmes in 22 countries: Current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. Int J Epidemiol 1998; 27: 735–742.

Collette HJ Day NE Rombach JJ De Waard F Evaluation of screening for breast cancer in a non-randomised study (the DOM project) by means of a case-control study. Lancet 1984;1:1224–1226.

Verbeek AL Hendriks JH Holland R Mravunac M Sturmans F Day NE Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975–1981). Lancet 1984; 1: 1222–1224.

Frisell J Glas U Hellstrom L Somell A Randomized mammographic screening for breast cancer in Stockholm. Design, first round results and comparisons. Breast Cancer Res Treat 1986; 8: 45–54.

Andersson I Aspegren K Janzon L Mammographic screening and mortality from breast cancer: The Malmo mammographic screening trial. BMJ 1988;297:943–948.

Tabar L Fagerberg CJ Gad A .: Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985; 1: 829–832.

Fracheboud J de Koning HJ Beemsterboer PM .: Nationwide breast cancer screening in The Netherlands: Results of initial and subsequent screening 1990–1995). National Evaluation Team for Breast Cancer Screening. Int J Cancer 1998; 75: 694–698.

Levi F Te VC Randimbison L La Vecchia C Trends of in situ carcinoma of the breast in Vaud, Switzerland. Eur J Cancer 1997;33:903–906.

Barchielli A Paci E Giorgi D Recent trends of in situ carcinoma of the breast and mammographic screening in the Florence area, Italy. Cancer Causes Control 1999;10:313–317.

Voogd AC Crommelin MA Repelaer Van Driel OJ Nolthenius-Puylaert Tutein MCBJE van der Heyden LH Coebergh JWW Trends in incidentie en behandelbeleid van ductaal carcinoma in situ van de mamma in Zuidoost-Nederland. Ned Tijdschr Geneeskd 2000;144:659–663.

Ernster VL Barclay J Kerlikowske K Grady D Henderson C Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996;275:913–918.

Adams-Cameron M Gilliland FD Hunt WC Key CR Trends in incidence and treatment for ductal carcinoma in situ in Hispanic, American Indian, and non-Hispanic white women in New Mexico, 1973–1994). Cancer 1999; 85: 1084–1090.

Julien JP Bijker N Fentiman IS .: Radiotherapy in breast-conserving treatment for breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000; 355: 528–533.

Verkooijen HM Peeters PH Buskens E Koot VC Borel Rinkes IH Mali WP van Vroonhoven T Diagnostic accuracy of large-core needle biopsy for nonpalpable breast disease: A meta-analysis. Br J Cancer 2000;82:1017–21.

Verkooijen HM Borel Rinkes IH Peeters PH Landheer ML van Es NJ Mali WP Klinkenbijl JH Van Vroonhoven TJ The COBRA Study Group. Impact of stereotactic large-core needle biopsy on diagnosis and surgical treatment of nonpalpable breast cancer. Eur J Surg Oncol 2001 Apr; 27(3):244–9.

O'Higgins N Linos DA Blichert-Toft M .: European Guidelines for quality assurance in the surgical management of mammographically detected lesions. European Breast Cancer Working Group. Eur J Surg Oncol 1998; 24: 96–98.

Perry N On behalf of the EUSOMA Working Party. Quality assurance in the diagnosis of breast disease. Eur J Cancer 2001; 37: 159–172.

Dixon JM Ravisekar O Cunningham M Anderson ED Anderson TJ Brown HK Factors affecting outcome of patients with impalpable breast cancer detected by breast screening. Br J Surg 1996;83:997–1001.

Bijker N Peterse JL Duchateau L Julien JP Fentiman IS Duval C Di Palma S Simony-Lafontaine J De Mascarel I Van de Vijver MJ Risk factors and metastasis after breast-conserving therapy for ductal carcinoma in situ; analysis of EORTC trial 10853. J. Clin Oncol 2001; 19: 2263–71.

Rutgers EJTh For the EUSOMA Consensus Group. Quality control in the loco-regional treatment of breast cancer. Eur Cancer 2001; 37: 447–453.

Van Dongen JA Fentiman IS Harris JR Holland R Peterse JL Salvadori B Stewart HJ In-situ breast cancer: The EORTC consensus meeting. Lancet 1989;8653:25–27.

Silverstein MJ Lagios MD Groshen S Waisman JR Lewinsky BS Martino S Gamagami P Colburn WJ The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340:1455–1461.

Schwartz GF Guiliano AE Veronesi U The Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymphnode biopsy and carcinoma of the breast. April 19–22, 2001 Philadelphia, Pennsylvania. Cancer 2002: 2542–2551.

Schwartz GF Solin LJ Olivotto IA Ernster VL Pressman PI Consensus conference on the treatment of in situ ductal carcinoma of the breast. April 22–25, 1999. Cancer 2000; 88: 946–954.

Fisher B Dignam J Wolmark N .: Lumpectomy and radi-ationtherapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441–452.

Fisher B Dignam J Wolmark N .: Tamoxifen in treatment of intraductal breast cancer: National Surgical Breast and Bowel Project B-24. Randomised controlled trial. Lancet 1999; 353: 1993–2000.